论文部分内容阅读
目的观察盐酸氨溴索联合布地奈德、糜蛋白酶雾化吸入辅助治疗小儿肺炎的疗效。方法将81例肺炎患儿随机分为治疗组和对照组,二组患儿均常规予抗感染、止咳、镇静等综合治疗,治疗组在抗感染等综合治疗的基础上加用盐酸氨溴索联合布地奈德、糜蛋白酶雾化吸入,比较二组患儿治疗后临床表现和治愈率。结果治疗组咳嗽、气促、肺部湿啰音消失、平均住院天数与对照组比较均有显著性差异(Pa<0.01)。治疗组痊愈38例(92.7%),对照组痊愈30例(75%),二组痊愈率比较有显著性差异(χ2=4.699 P<0.01)。二组均未见不良反应。结论盐酸氨溴索联合布地奈德、糜蛋白酶雾化吸入辅助治疗小儿肺炎安全有效。
Objective To observe the efficacy of ambroxol hydrochloride combined with budesonide and chymotrypsin inhalation in the treatment of children with pneumonia. Methods Eighty-one children with pneumonia were randomly divided into treatment group and control group. The two groups of children were routinely given anti-infective, cough and sedation treatment. The treatment group was treated with ambroxol hydrochloride Combined budesonide, chymotrypsin inhalation, the clinical manifestations and cure rates of two groups of children after treatment were compared. Results The treatment group cough, shortness of breath, lung wet rales disappeared, the average length of stay compared with the control group were significantly different (Pa <0.01). There were 38 cases (92.7%) in the treatment group and 30 cases (75%) in the control group. There was significant difference between the two groups (χ2 = 4.699 P <0.01). No adverse reactions in both groups. Conclusion Ambroxol hydrochloride combined with budesonide, chymotrypsin inhalation adjuvant treatment of children with pneumonia is safe and effective.